Appili announces dosing of first patient in phase 3 Covid-19 trial

This article was originally published here

PRA Health Sciences, a clinical research organisation (CRO) selected by Appili, will conduct the trial at 47 outpatient sites. Avigan, which is an antiviral in oral tablet form

The post Appili announces dosing of first patient in phase 3 Covid-19 trial appeared first on Pharmaceutical Business review.